NCT01832415已完成不适用
Non Interventional Study Dealing With the Use of Bevacizumab (Avastin®) in Patients With Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal and Treated in First-line Therapy
ARCAGY/ GINECO GROUP14 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2013年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 500
- 试验地点
- 14
- 主要终点
- Safety according to CTCAE v4.0 criteria
研究概览
简要总结
The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (Avastin ®)
详细描述
Population: Patients aged 18 years and older with an epithelial ovarian cancer, fallopian tube or primary peritoneal or witch it was decided to initiate a process comprising of Bevacizumab (Avastin ®) in first-line therapy
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients aged 18 years and over,
- •Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will receive bevacizumab (Avastin ®) in first-line therapy
- •Patients should be informed of the study orally and should not have any objection their data to be processed.
排除标准
- •Patient participation in a clinical trial
- •Patient non-affiliated to a social security scheme.
研究组 & 干预措施
Use of bevacizumab (Avastin ®) - First-line ovarian cancer
Patient receiving bevacizumab in ovarian cancer first line treatment
干预措施: Bevacizumab (Drug)
结局指标
主要结局
Safety according to CTCAE v4.0 criteria
时间窗: Patient will be followed dureing 36 months
To assess patient safety and the tolerance of bevacizumab andministered regarding the daily practice of the oncologist.
次要结局
- Indication and cons indication of bevacizumab in clinical practice(At registration)
- Efficacy(Patient will be followed during 36 months)
- Evaluation of the modality of use of bevacizumab(The patients will be followed during 36 months)
- Efficacy of treatment at relapse(Patient will be followed during 36 months)
- Characteristics of the population registered(At registration)
- Evaluation of monitoring practices of bevacizumab(The patients will be followed during 36 months)
研究者
研究点 (14)
Loading locations...
相似试验
已完成
不适用
Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)Ovarian CancerNCT02163720ARCAGY/ GINECO GROUP101
进行中（未招募）
不适用
The Belgian REAL (BE.REAL) RegistryAtherosclerotic Cardiovascular DiseaseNCT05726838Novartis Pharmaceuticals600
已完成
不适用
To study the effect of spinal anaesthesia and the changes in vital characteristics caused by it in patients with long standing renal disorder.CTRI/2019/02/017444lokmanya tilak municipal medical college and general hospital
已完成
不适用
Prospective Multicentre Non-interventional Study of VANTAS® for the Treatment of Patients With Advanced Prostate CancerProstate CancerNCT01574846Orion Corporation, Orion Pharma142
Unknown
不适用
A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase InhibitorsNon-small Cell Lung Cancer MetastaticNCT03424980Tang-Du Hospital200